{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-24-000183","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.521904+00:00","generated_at":"2026-05-30T03:42:04.556085+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Immunovant announces five IND clearances for IMVT-1402 and plans to initiate registrational trials by March 2025","bullets":["Five INDs cleared for IMVT-1402 across therapeutic areas including Graves' disease and rheumatoid arthritis.","Proof-of-concept data from batoclimab in Graves' disease showed 60% response rate at week 2; registrational trial for IMVT-1402 expected by year-end 2024.","Initiation of potentially registrational trial for IMVT-1402 in difficult-to-treat RA expected by March 31, 2025.","Batoclimab trials in MG and CIDP fully enrolled; data disclosures by March 31, 2025.","Appointed Melanie Gloria as COO effective Nov 18, 2024; net loss $109.1M for quarter ended Sept 30, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-24-000183","json":"https://secwatch.observer/filing/0001764013-24-000183.json","markdown":"https://secwatch.observer/filing/0001764013-24-000183.md","text":"https://secwatch.observer/filing/0001764013-24-000183.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000183/0001764013-24-000183-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401324000183/imvt-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:42:04.556085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}